Cargando…
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376394/ https://www.ncbi.nlm.nih.gov/pubmed/27578330 http://dx.doi.org/10.1007/s10928-016-9486-9 |
_version_ | 1782519148468764672 |
---|---|
author | Sadiq, Muhammad W. Nielsen, Elisabet I. Khachman, Dalia Conil, Jean-Marie Georges, Bernard Houin, Georges Laffont, Celine M. Karlsson, Mats O. Friberg, Lena E. |
author_facet | Sadiq, Muhammad W. Nielsen, Elisabet I. Khachman, Dalia Conil, Jean-Marie Georges, Bernard Houin, Georges Laffont, Celine M. Karlsson, Mats O. Friberg, Lena E. |
author_sort | Sadiq, Muhammad W. |
collection | PubMed |
description | The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model. The WB-PBPK model was built using a non-linear mixed effects approach based on data from 102 adult intensive care unit patients. Tissue to plasma distribution coefficients (Kp) were available from the literature and used as informative priors. The developed WB-PBPK model successfully characterized both the typical trends and variability of the available ciprofloxacin plasma concentration data. The WB-PBPK model was thereafter combined with a pharmacokinetic–pharmacodynamic (PKPD) model, developed based on in vitro time-kill data of ciprofloxacin and Escherichia coli to illustrate the potential of this type of approach to predict the time-course of bacterial killing at different sites of infection. The predicted unbound concentration–time profile in extracellular tissue was driving the bacterial killing in the PKPD model and the rate and extent of take-over of mutant bacteria in different tissues were explored. The bacterial killing was predicted to be most efficient in lung and kidney, which correspond well to ciprofloxacin’s indications pneumonia and urinary tract infections. Furthermore, a function based on available information on bacterial killing by the immune system in vivo was incorporated. This work demonstrates the development and application of a WB-PBPK–PD model to compare killing of bacteria with different antibiotic susceptibility, of value for drug development and the optimal use of antibiotics . ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10928-016-9486-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5376394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-53763942017-04-12 A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection Sadiq, Muhammad W. Nielsen, Elisabet I. Khachman, Dalia Conil, Jean-Marie Georges, Bernard Houin, Georges Laffont, Celine M. Karlsson, Mats O. Friberg, Lena E. J Pharmacokinet Pharmacodyn Original Paper The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model. The WB-PBPK model was built using a non-linear mixed effects approach based on data from 102 adult intensive care unit patients. Tissue to plasma distribution coefficients (Kp) were available from the literature and used as informative priors. The developed WB-PBPK model successfully characterized both the typical trends and variability of the available ciprofloxacin plasma concentration data. The WB-PBPK model was thereafter combined with a pharmacokinetic–pharmacodynamic (PKPD) model, developed based on in vitro time-kill data of ciprofloxacin and Escherichia coli to illustrate the potential of this type of approach to predict the time-course of bacterial killing at different sites of infection. The predicted unbound concentration–time profile in extracellular tissue was driving the bacterial killing in the PKPD model and the rate and extent of take-over of mutant bacteria in different tissues were explored. The bacterial killing was predicted to be most efficient in lung and kidney, which correspond well to ciprofloxacin’s indications pneumonia and urinary tract infections. Furthermore, a function based on available information on bacterial killing by the immune system in vivo was incorporated. This work demonstrates the development and application of a WB-PBPK–PD model to compare killing of bacteria with different antibiotic susceptibility, of value for drug development and the optimal use of antibiotics . ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10928-016-9486-9) contains supplementary material, which is available to authorized users. Springer US 2016-08-30 2017 /pmc/articles/PMC5376394/ /pubmed/27578330 http://dx.doi.org/10.1007/s10928-016-9486-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Sadiq, Muhammad W. Nielsen, Elisabet I. Khachman, Dalia Conil, Jean-Marie Georges, Bernard Houin, Georges Laffont, Celine M. Karlsson, Mats O. Friberg, Lena E. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
title | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
title_full | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
title_fullStr | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
title_full_unstemmed | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
title_short | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
title_sort | whole-body physiologically based pharmacokinetic (wb-pbpk) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376394/ https://www.ncbi.nlm.nih.gov/pubmed/27578330 http://dx.doi.org/10.1007/s10928-016-9486-9 |
work_keys_str_mv | AT sadiqmuhammadw awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT nielsenelisabeti awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT khachmandalia awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT coniljeanmarie awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT georgesbernard awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT houingeorges awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT laffontcelinem awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT karlssonmatso awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT friberglenae awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT sadiqmuhammadw wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT nielsenelisabeti wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT khachmandalia wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT coniljeanmarie wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT georgesbernard wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT houingeorges wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT laffontcelinem wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT karlssonmatso wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection AT friberglenae wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection |